Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of ketamine, lidocaine, and dexmedetomidine is used as an intravenous admixture for opioid-free anesthesia and multimodal pain management. This mixture leverages the synergistic effects of its components to provide analgesia and sedation while minimizing opioid requirements. Ketamine acts primarily as an NMDA receptor antagonist, providing dissociative anesthesia and potent analgesia. Lidocaine is a sodium channel blocker with local anesthetic and systemic analgesic properties. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist that provides sedation, anxiolysis, and additional analgesia without significant respiratory depression. The combination has been studied for perioperative pain control in both human and veterinary medicine[2][3][9]. It is typically prepared in specific concentrations (e.g., 1 µg/mL dexmedetomidine, 1 mg/mL ketamine, 10 mg/mL lidocaine) for intravenous infusion[2]. This admixture aims to reduce opioid consumption during surgery by providing effective multimodal anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketamine + lidocaine + dexmedetomidine.